Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus gastroenteritis among children in Uganda.

ABSTRACT:

Background

The underlying causes for lower rotavirus vaccine effectiveness (VE) in high-child-mortality settings are not well understood. Uganda introduced the human monovalent G1P[8] rotavirus vaccine (Rotarix) in June 2018. We determined the effectiveness of Rotarix against rotavirus diarrhea requiring hospital care among Ugandan children.

Methods

We compared the vaccination status of children with laboratory-confirmed rotavirus (cases) and non-rotavirus (controls) diarrhea who were age-eligible to receive Rotarix and admitted to 3 hospitals in Uganda October 2018-December 2022. VE ([1-odds ratio of vaccination among cases and controls] x 100]) was calculated using unconditional logistic regression adjusting for age, birth month-year, and hospital.

Results

Among 187

SUBMITTER: Aanyu HT 

PROVIDER: S-EPMC11848724 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature